AstraZeneca - Fourth Quarter and Full Year Results 2012

LONDON, Jan. 31, 2013 - Financial performance for the full year reflects the loss of exclusivity on several brands. At constant exchange rates (CER), revenue declined by 15 percent and Core EPS declined by 9 percent Brilinta/Brilique, Symbicort,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news